NANOMATERIALES Y POLIMEROS SL

Their core work

NANOMYP is a Spanish private SME specialising in the design and synthesis of advanced nanomaterials and functional polymers. Their core work covers soft biocompatible polymer nanostructures — including nanogels and self-assembling systems — with applications in pharmaceutical delivery, particularly ocular drug delivery. More recently, they have contributed expertise in biocatalysis and enzyme immobilisation for biorefinery and green chemistry processes. They operate as a specialist technical partner in European research consortia, bringing nanoscale materials knowledge to training networks and staff exchange programmes.

What they specialise in

How they've shifted over time

In their earliest H2020 engagement (NanoPol, 2019), NANOMYP focused squarely on pharmaceutical-grade soft matter: nanogels, self-assembled polymer systems, and biocompatible nanocarriers for drug delivery in ophthalmology. Their second project (INTERfaces, 2020) marked a deliberate expansion toward industrial biotechnology — enzyme immobilisation, biocatalytic cascades, and biorefineries — signalling a broadening from healthcare applications into sustainable chemistry. This trajectory suggests the company is repositioning its materials expertise from biomedical niches toward green industrial processes, which is a meaningful strategic shift for a small specialised SME.

NANOMYP is moving from biomedical nanomaterials toward industrial biotechnology, making them an increasingly relevant partner for green chemistry, biorefinery, and sustainable manufacturing projects.

How they like to work

NANOMYP has participated exclusively as a consortium member — never as a coordinator — across both H2020 projects, both within MSCA schemes (RISE and ITN) which are inherently multi-partner training and mobility networks. Their 29 unique partners across 15 countries indicate a broad European scientific network for a company of their size, though this breadth is partly a structural feature of MSCA programmes rather than evidence of an independent partnership strategy. There is no evidence of repeat partnerships, consistent with the exploratory mobility logic of the MSCA instrument.

NANOMYP has worked with 29 distinct partners across 15 countries — a wide European reach for a two-project SME, largely attributable to the inherently multinational structure of the MSCA-RISE and MSCA-ITN programmes they joined.

What sets them apart

As a private SME rather than a university or public research institute, NANOMYP brings industrial-scale materials manufacturing perspective into academically led consortia — a combination that MSCA and applied research networks actively seek. Their unusual dual coverage of pharmaceutical nanocarriers and biocatalytic systems means they can bridge biomedical and green chemistry work streams within the same project, which is rare at this company size. Located in Granada, they likely maintain close working ties with the University of Granada's materials science and chemistry infrastructure.

Highlights from their portfolio

• NanoPol
  NANOMYP's foundational H2020 engagement, running the full 2019–2024 period via an MSCA-RISE staff exchange, positioned them at the intersection of soft matter science and nano-pharma for ophthalmology applications.
• INTERfaces
  Their participation in this MSCA-ITN training network on biocatalytic cascades represents a deliberate strategic expansion into enzyme technology and biorefineries, signalling an active broadening beyond pure polymer science.